Patents by Inventor Martin V. Haspel
Martin V. Haspel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8343508Abstract: This invention provides botulinum antitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. The botulinum antitoxin is prepared by inoculating an animal with a monovalent botulinum toxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all seven botulinum serotypes are then combined to produce a high titered heptavalent botulinum antitoxin composition.Type: GrantFiled: December 11, 2009Date of Patent: January 1, 2013Assignee: Intracel Holdings LLCInventors: Nicholas Pomato, Martin V. Haspel, Janet H. Ransom
-
Publication number: 20100150934Abstract: This invention provides botulinum antitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. The botulinum antitoxin is prepared by inoculating an animal with a monovalent botulinum toxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all seven botulinum serotypes are then combined to produce a high titered heptavalent botulinum antitoxin composition.Type: ApplicationFiled: December 11, 2009Publication date: June 17, 2010Inventors: Nicholas Pomato, Martin V. Haspel, Janet H. Ransom
-
Patent number: 7628996Abstract: This invention relates to methods of removing bioburden from an aggregate of cells to obtain sterile cells that remain viable and immunogenic for the production of vaccines. This invention further relates to a method of eliciting an immune response to prevent a recurrence of metastases that involves preparing and administering a sterile vaccine derived from solid tumors. The vaccine is prepared by excising a solid tumor from a cancer patient, digesting the tumor cells with an enzyme to obtain dissociated cells, irradiating the dissociated cells to render the cells non-tumorigenic, and sterilizing the cells.Type: GrantFiled: February 21, 2003Date of Patent: December 8, 2009Assignee: Intracel Resources LLCInventors: Martin V. Haspel, Nicholas Pomato, Michael G. Hanna, Jr.
-
Publication number: 20030228300Abstract: This invention relates to methods of removing bioburden from an aggregate of cells to obtain sterile cells that remain viable and immunogenic for the production of vaccines. This invention further relates to a method of eliciting an immune response to prevent a recurrence of metastases that involves preparing and administering a sterile vaccine derived from solid tumors. The vaccine is prepared by excising a solid tumor from a cancer patient, digesting the tumor cells with an enzyme to obtain dissociated cells, irradiating the dissociated cells to render the cells non-tumorigenic, and sterilizing the cells.Type: ApplicationFiled: February 21, 2003Publication date: December 11, 2003Inventors: Martin V. Haspel, Nicholas Pomato, Michael G. Hanna
-
Patent number: 5951985Abstract: This invention relates to the epitopes to which monoclonal antibody 88BV59 and antibody 16.88 react. These antibodies were produced by B-cell lines derived from B-cells of cancer patients actively immunized with autologous tumor antigens. Both epitopes are found on the same antigen in tumor tissue. These epitopes can be used in both diagnostic procedures and therapy for human cancers.Type: GrantFiled: August 19, 1997Date of Patent: September 14, 1999Assignee: Perimmune Holdings, Inc.Inventors: Sandra M. Butler, Nicholas Pomato, Ebo Bos, Michael G. Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
-
Patent number: 5495002Abstract: This invention relates to transformed B-cell lines derived from peripheral blood B-cells of cancer patients actively immunized with autologous tumor antigen and the monoclonal antibodies they produce. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.Type: GrantFiled: February 22, 1994Date of Patent: February 27, 1996Assignee: Akzo N.V.Inventors: Barry J. Kobrin, Martin V. Haspel
-
Patent number: 5474755Abstract: This invention relates to monoclonal antibody 88BV59 produced by B-cell lines derived from B-cells of cancer patients actively immunized with autologous tumor antigen. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.Type: GrantFiled: May 24, 1995Date of Patent: December 12, 1995Assignee: Akzo Nobel N.V.Inventors: Michael G. Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr., Marie E. Dembinsky, Barry J. Kobrin
-
Patent number: 5348880Abstract: This invention relates to human monoclonal antibody 81AV78 produced by a transformed B-cell line, having ATCC accession number CRL 10750 derived from B-cells of cancer patients actively immunized with autologous tumor antimen. This monoclonal antibody can be used in both diagnostic procedures and therapy for human cancers.Type: GrantFiled: July 20, 1993Date of Patent: September 20, 1994Assignee: Akzo N.V.Inventors: Michael G. Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
-
Patent number: 5338832Abstract: The present invention comprises the epitope recognized by the human monoclonal antibody 16-18, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and anti-idiotypic antibodies to human MCA 16-88, which comprise the same epitope. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring of treatment of cancer and to the use of this antigen in the preparation of vaccines to elicit an immune response similar to that obtained against tumor cells containing this epitope.Type: GrantFiled: August 13, 1992Date of Patent: August 16, 1994Assignee: Akzo N.V.Inventors: Nicholas Pomato, Ebo S. Bos, Martin V. Haspel, Michael G. Hanna, Jr., Michael L. Berman
-
Patent number: 5180814Abstract: A human monoclonal antibody having specificity for an epitope in a tumor associated antigen, said antibody produced by a cell line selected from the group consisting of Co6a3-1 (HB8493), Co7a4 (HB8494), Co28A32 (HB9380), Co16-86 (HB8496), and Co16-88 (HB8495).Type: GrantFiled: January 22, 1991Date of Patent: January 19, 1993Assignee: Akzo N.V.Inventors: Michael Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
-
Patent number: 5106738Abstract: A method for producing a human B-lymphocyte that is able to grow in cell culture and produces human monoclonal antibodies having binding specificity for tumor-associated antigens by exposing a human B-lymphocyte to a tumor cell antigen in a vaccine containing viable human tumor cells that have been made non-tumorigenic, and immortalizing the exposed B-lymphocyte by exposing to a transforming agent for sufficient time to transform the B-lymphocyte.Type: GrantFiled: January 25, 1989Date of Patent: April 21, 1992Assignee: AKZO NVInventors: Michael G. Hanna, Jr., Martin V. Haspel, Jr., Herbert C. Hoover, Jr.
-
Patent number: 4997762Abstract: Hybridoma cell lines and transformed B-cell lines are derived from B-cells of cancer patients actively immunized with autologous tumor antigens and used to produce monoclonal antibodies having specificity for tumor-associated antigens. The monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.Type: GrantFiled: April 15, 1987Date of Patent: March 5, 1991Assignee: Akzo N.V.Inventors: Michael Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
-
Patent number: 4849506Abstract: Leukoregulin is identified, a biologically active lymphokine of molecular weight of about 120,000 to 140,000, with subunits of about 30,000 to 35,000, having the isoelectric focusing pH's of between 4.8 and 5.5 or between 7.5 and 8.3, which has the ability to regulate tumor cell physiology and growth without affecting the growth of normal cells. Methods for stimulating its production by monouclear cells, methods for its isolation and purification, and methods for its therapeutic uses are also disclosed.Type: GrantFiled: September 11, 1986Date of Patent: July 18, 1989Assignee: Akzo N.V.Inventors: Janet H. Ransom, Richard P. McCabe, Martin V. Haspel, Nicholas Pomato
-
Patent number: 4828991Abstract: Monoclonal antibodies produced by hybridoma or transformed B-cell lines deriveed from B-cells of cancer patients actively immunized with autologous tumor antigen. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.Type: GrantFiled: January 31, 1985Date of Patent: May 9, 1989Assignee: Akzo N.V.Inventors: Michael Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.